BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.

百济神州决定停止开发其靶向TIGIT的药物ociperlimab，这是该药物类别遭遇的又一次挫折。

The Nasdaq-listed company – which is planning to rebrand as BeOne Medicines – said that the decision follows a futility analysis of the phase 3 AdvanTIG-302 trial of ociperlimab (BGB-A1217) by the study's independent data monitoring committee which indicated the drug was unlikely to show an improvement in overall survival..

这家在纳斯达克上市的公司（计划更名为BeOne Medicines）表示，这一决定是基于独立数据监察委员会对ociperlimab（BGB-A1217）三期临床试验AdvanTIG-302进行的无效性分析，结果显示该药物不太可能显示出总生存期的改善。

AdvanTIG-302 was pitting the combination of ociperlimab with BeiGene's PD-1 inhibitor Tevimbra (tislelizumab) against MSD's $29.5 billion-a-year PD-1 inhibitor Keytruda (pembrolizumab) in previously untreated, advanced PD-L1-positive non-small cell lung cancer (NSCLC).

AdvanTIG-302研究正在将ociperlimab与百济神州的PD-1抑制剂替雷利珠单抗（Tevimbra）联合使用，与默沙东年销售额达295亿美元的PD-1抑制剂Keytruda（帕博利珠单抗）进行对比，用于既往未经治疗、PD-L1阳性的晚期非小细胞肺癌（NSCLC）。

'We evaluate our clinical programmes to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritising others,' said Mark Lanasa, BeiGene's chief medical officer.

“我们评估我们的临床项目，将资源集中在最有希望的、具有临床差异化的候选药物上，同时经过深思熟虑后降低其他项目的优先级，”百济神州首席医学官Mark Lanasa表示。

'Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide.'

“我们的承诺依然坚定不移：发现和开发更实惠、更易获得的创新治疗方法，惠及全球癌症患者。”

The decision follows negative results in other ociperlimab trials, so isn't wholly unexpected, but is another example of the difficulties companies are facing in developing additional checkpoint inhibitors that work alongside the PD-1/PD-L1 inhibitors which currently dominate the cancer immunotherapy category..

该决定是在其他 ociperlimab 试验结果不佳之后做出的，因此并不完全出乎意料，但这也是公司正在面临的开发与目前主导癌症免疫治疗类别的 PD-1/PD-L1 抑制剂协同工作的额外检查点抑制剂的困难的另一个例子。

TIGIT

in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody

特别是被证明是药物开发人员的一个棘手目标，而百济神州的决定是在默克公司放弃其抗TIGIT抗体开发的几个月后做出的。

vibostolimab

振动棒单抗

after a series of disappointing trial results, along with its anti-LAG-3 candidate favezelimab.

在一系列令人失望的试验结果之后，其抗LAG-3候选药物favezelimab也表现不佳。

Last year, Bristol Myers Squibb also returned rights to

去年，百时美施贵宝公司也归还了权利给

AGEN1777

, a TIGITxCD96 bispecific antibody partnered with Agenus in a $1.56 billion deal, saying the intention was to 'realign' its product pipeline.

，一种与Agenus合作的价值15.6亿美元的TIGITxCD96双特异性抗体，称其目的是“重新调整”其产品管线。

Other TIGIT drugs from Roche and Gilead/Arcus meanwhile have also suffered setbacks in first-line NSCLC, with Roche now focusing its efforts with tiragolumab on liver and oesophageal cancers after the drug seemed to worsen outcomes in an NSCLC study.

与此同时，罗氏和吉利德/Arcus的其他TIGIT药物在一线非小细胞肺癌（NSCLC）中也遭遇了挫折，此前一项NSCLC研究显示tiragolumab似乎恶化了治疗结果，因此罗氏现在将其研发重点转向肝癌和食管癌。

After one phase 3 trial failure, Gilead/Arcus still has one study remaining for its domvanalimab antibody in this setting, alongside a phase 3 trial in upper gastrointestinal cancer, with active programmes in first-line NSCLC also ongoing for iTeos/GSK's

在一项三期试验失败后，吉利德/Arcus公司在此适应症上仍有另一项关于domvanalimab抗体的研究正在进行中，同时还在上消化道癌症中进行着一项三期试验，而iTeos/GSK在一线非小细胞肺癌的项目也在持续推进。

belrestotug

贝尔雷斯特图格

antibody and AstraZeneca's TIGITxPD-1 bispecific antibody

抗体和阿斯利康的TIGITxPD-1双特异性抗体

rilvegostomig

里尔韦戈斯托米吉

.

BeiGene said it would present the results from AdvanTIG-302 at a future medical congress 'to help advance science and the understanding of anti-TIGIT activity.'

百济神州表示，将在未来的医学大会上展示AdvanTIG-302的研究结果，“以帮助推动科学和对anti-TIGIT活性的理解。”